Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAFV600E-mutated anaplastic thyroid carcinoma.

CONCLUSIONS: We report the first series in the literature of BRAFV600E-mutated ATC patients with locoregionally advanced disease treated with dabrafenib and trametinib followed by surgical resection. We demonstrated feasibility of complete ATC resection, decreased need for tracheostomy, high pathologic response rates, and durable locoregional control with symptom amelioration. PMID: 31319771 [PubMed - as supplied by publisher]
Source: Thyroid : official journal of the American Thyroid Association - Category: Endocrinology Tags: Thyroid Source Type: research